Pacer Advisors Inc. Increases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Pacer Advisors Inc. raised its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,730,771 shares of the biotechnology company's stock after buying an additional 450,949 shares during the quarter. Pacer Advisors Inc. owned about 7.33% of Ironwood Pharmaceuticals worth $51,967,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. KBC Group NV grew its stake in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock worth $35,000 after buying an additional 3,198 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $53,000. Diversified Trust Co purchased a new position in Ironwood Pharmaceuticals in the third quarter worth $52,000. Wolverine Trading LLC bought a new position in Ironwood Pharmaceuticals in the third quarter valued at $51,000. Finally, Algert Global LLC bought a new stake in Ironwood Pharmaceuticals during the second quarter worth about $93,000.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the transaction, the chief financial officer now directly owns 309,572 shares of the company's stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 12.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

IRWD has been the topic of several recent research reports. Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 22nd. JMP Securities decreased their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a research note on Thursday. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.67.

Ironwood Pharmaceuticals Trading Up 1.5 %

NASDAQ IRWD traded up $0.04 on Friday, hitting $2.34. The company's stock had a trading volume of 3,504,106 shares, compared to its average volume of 2,237,363. Ironwood Pharmaceuticals, Inc. has a 52-week low of $2.23 and a 52-week high of $15.70. The firm has a market cap of $373.67 million, a P/E ratio of -77.83 and a beta of 0.34. The company's 50-day simple moving average is $3.88 and its 200 day simple moving average is $4.48.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. During the same quarter last year, the company posted $0.12 earnings per share. The firm's revenue for the quarter was down 19.4% compared to the same quarter last year. On average, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.